List of bibliographic references
Number of relevant bibliographic references: 7.
| Ident. | Authors (with country if any) | Title |
|---|
| 000400 (2019) |
Thomas Frisell [Suède] ; Johan Askling [Suède] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. |
| 000471 (2019) |
Thomas Frisell [Suède] ; Johan Askling [Suède] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. |
| 000523 (2019) |
Thomas Frisell [Suède] ; Mats Dehlin ; Daniela Di Giuseppe [Suède] ; Nils Feltelius ; Carl Turesson ; Johan Askling [Suède] | Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. |
| 000541 (2019) |
Kathrine Lederballe Gr N [Oman] ; Elizabeth V. Arkema [Suède] ; Bente Glintborg [Danemark] ; Frank Mehnert [Danemark] ; Mikkel Stergaard [Danemark] ; Lene Dreyer [Danemark] ; Mette N Rgaard [Danemark] ; Niels Steen Krogh [Danemark] ; Johan Askling [Suède] ; Merete Lund Hetland [Danemark] | Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. |
| 000921 (2018) |
Thomas Frisell [Suède] ; Eva Baecklund [Suède] ; Karin Bengtsson [Suède] ; Daniela Di Giuseppe [Suède] ; Helena Forsblad-D'Elia [Suède] ; Johan Askling [Suède] | Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. |
| 000A01 (2017) |
Hjalmar Wadström [Suède] ; Thomas Frisell [Suède] ; Johan Askling [Suède] | Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. |
| 000E30 (2017) |
Louise K. Mercer [Royaume-Uni] ; Johan Askling [Suède] ; Pauline Raaschou [Suède] ; William G. Dixon [Royaume-Uni] ; Lene Dreyer [Danemark] ; Merete Lund Hetland [Danemark] ; Anja Strangfeld [Allemagne] ; Angela Zink [Allemagne] ; Xavier Mariette [France] ; Axel Finckh [Suisse] ; Helena Canhao [Portugal] ; Florenzo Iannone [Italie] ; Jakub Zavada [République tchèque] ; Jacques Morel [France] ; Jacques-Eric Gottenberg [France] ; Kimme L. Hyrich [Royaume-Uni] ; Joachim Listing [Allemagne] | Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i -k "Johan Askling"
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i \
-Sk "Johan Askling" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PubMed
|étape= Curation
|type= indexItem
|index= Author.i
|clé= Johan Askling
}}
| This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021 |  |
